Aventis Ketek Recommended For Pneumonia, Sinusitis, And Bronchitis
Executive Summary
Aventis' Ketek should gain approval for the treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute sinusitis, FDA's Anti-Infective Drugs Advisory Committee agreed Jan. 8
You may also be interested in...
Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded
FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications
Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded
FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications
Aventis Ketek July Launch Will Highlight Targeted Antibacterial Activity
Aventis' promotional message for Ketek will center on the antibiotic's ability to specifically target all pathogens commonly associated with respiratory tract infections without affecting other bacterial strains